Biotech exposure from discovery to contract manufacturing, tiered by what stage the business is actually at.
Core — the theme IS a principal business todayGrowing — real operations, not yet the main businessAnnounced — committed plans or orders, little revenue yetMention-only — appears only as outlook language
Biocon Limited.PharmaceuticalsCore business₹67,361 CrP/E 111.1 vs 28.5ROCE 0.9%
Biocon is a biopharmaceutical company whose core business is biosimilars, biologics and complex generics — biosimilars alone contributed 60% of FY26 business revenue.
“Biosimilars: D 104,312 million, (USD 1.18 billion) Growth 16%”
+1 more quote from the report
“we have invested significantly to build end-to-end capabilities across R&D, manufacturing and commercial execution, with biosimilars as our core growth engine, alongside selective investments in generics where we have differentiated capabilities.”
Sai Life SciencesPharmaceuticalsCore business₹30,856 CrP/E 75.1 vs 28.5ROCE 16.7%
Sai Life Sciences is a fully integrated CRDMO whose entire business is providing discovery, development, and manufacturing services to global pharmaceutical and biotechnology innovator clients (300+ including 18 of the top 25 big pharma).
“We serve global pharmaceutical and biotechnology companies with customized solutions that accelerate the journey of molecules from discovery to the market for a healthier tomorrow.”
Cohance LifesciencesPharmaceuticalsCore business₹17,690 CrP/E 157.3 vs 28.5ROCE 4.1%
Cohance is a fully integrated global CDMO providing development and manufacturing services for biologics modalities including oligonucleotides, bioconjugation, and complex APIs/ADCs, representing its principal business.
“Cohance Lifesciences is a fully integrated global CDMO, partnering with leading innovators across the entire product lifecycle- from route scouting and early development to commercial manufacturing. With advanced capabilities in oligonucleotides, bioconjugation and complex small molecules, we address some of the most challenging chemistries in the industry.”
+1 more quote from the report
“Cohance is well-positioned in high-growth verticals such as ADCs, oligonucleotides and specialty APIs, aligned with global innovation trends.”
How this list is built
Definition used: Discovers, develops or manufactures biologic drugs, vaccines, biosimilars, cell/gene therapies, or provides biotech CRO/CDMO services.Membership is extracted from each company’s newest annual report; every quote is validated against the report page before publishing, and core/growing tiers are confirmed by a second independent read (marked ). Companies whose reports our corpus hasn’t read yet simply aren’t listed — absence means unread, not “no exposure”.
MarketPing publishes facts, filings and measured history only — nothing on this page is investment advice, a recommendation or a rating.
